微创保留子宫肌瘤治疗后性功能结局:系统综述与荟萃分析
本系统综述与荟萃分析评估微创保留子宫的肌瘤治疗后性功能结局,纳入4项研究共382名育龄女性,采用FSFI和BISF-W等验证工具评估。随机效应荟萃分析提示术后性功能改善(SMD 0.65;95%CI 0.28-1.03;p=0.001),但异质性高(I²=90.3%),证据以观察性研究为主,结论应视为探索性。
要点
- 微创保留子宫肌瘤治疗后性功能可能改善,SMD 0.65(95%CI 0.28-1.03;p=0.001)。
- 证据仅基于4项观察性研究、382名女性,异质性高(I²=90.3%)。
- 需更大规模前瞻性研究采用标准化结局报告予以确认。
核心结论
- 现有证据提示微创保留子宫的肌瘤治疗可能与术后性功能改善相关。
- 因纳入研究少、以观察性证据为主且异质性大,结论应视为探索性。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA 2020指南并在PROSPERO前瞻性注册(CRD420261392260)。
- 检索PubMed/MEDLINE、Scopus和Google Scholar,自建库至最终检索日。
- 纳入育龄女性接受微创保留子宫肌瘤治疗并使用验证工具报告术后性功能和/或其他患者报告结局的研究。
- 最终纳入4项研究共382名女性进行定量合成。
主要发现
- 性功能主要采用女性性功能指数(FSFI)和女性性功能简要指数(BISF-W)评估。
- 随机效应荟萃分析显示术后性功能改善,标准化均数差(SMD)0.65(95%CI 0.28-1.03;p=0.001)。
- 异质性显著(I²=90.3%)。
- 因纳入研究数量有限,无法可靠评估发表偏倚。
关键数值与推荐
- 术后性功能改善的合并效应量:SMD 0.65(95%CI 0.28-1.03;p=0.001)。
- 异质性:I²=90.3%。
临床怎么用
- 临床咨询时可告知患者微创保留子宫肌瘤治疗可能改善术后性功能,但证据等级有限。
- 应结合个体情况谨慎解读,并关注盆腔疼痛等其他患者报告结局。
局限性
- 仅纳入4项研究,样本量有限(382名女性)。
- 多数为观察性研究,证据等级受限。
- 异质性高(I²=90.3%)。
- 因研究数量少无法可靠评估发表偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate postoperative sexual function outcomes following minimally invasive uterus-preserving treatments for uterine fibroids and to quantitatively synthesize the available evidence using validated patient-reported outcome measures, while narratively summarizing other patient-reported outcomes, including pelvic pain. DATA SOURCES: A systematic literature search was conducted in PubMed/MEDLINE, Scopus, and Google Scholar from database inception to the final search date. The review was conducted in accordance with the PRISMA 2020 guidelines and prospectively registered in PROSPERO (CRD420261392260). METHODS OF STUDY SELECTION: Studies including reproductive-age women undergoing minimally invasive uterus-preserving fibroid treatment and reporting postoperative sexual function and/or other patient-reported outcomes, including pelvic pain, using validated instruments were eligible. Studies without extractable quantitative data for sexual function outcomes were excluded. Two reviewers independently screened studies and extracted data. TABULATION, INTEGRATION AND RESULTS: Sixty-seven records were identified, and 11 full-text articles were assessed for eligibility. Four studies involving 382 women met the inclusion criteria and were included in the quantitative synthesis. Sexual function was primarily assessed using the Female Sexual Function Index (FSFI) and the Brief Index of Sexual Functioning for Women (BISF-W). Random-effects meta-analysis suggested an improvement in postoperative sexual function following treatment (standardized mean difference [SMD] 0.65; 95% confidence interval [CI], 0.28-1.03; p = 0.001). However, these findings should be interpreted cautiously because only four studies were included, most of which were observational, and substantial heterogeneity was present (I² = 90.3%). Publication bias could not be reliably assessed because of the limited number of included studies. CONCLUSION: The available evidence suggests that minimally invasive uterus-preserving fibroid treatments may be associated with improved postoperative sexual function. However, these findings should be interpreted as exploratory, given the limited number of included studies, the predominance of observational evidence, and substantial heterogeneity. Larger prospective studies with standardized outcome reporting are needed to confirm these findings.
引用
- Deligeoroglou E, Zouridis A, Tsiapakidou S, et al. Sexual Function Outcomes After Minimally Invasive Uterus-Preserving Fibroid Treatment: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2026. PMID: 42822831. doi:10.1016/j.jmig.2026.09.467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。